Orchestra BioMed™ Adds Seasoned Biotech Executive Pamela Yanchik Connealy to Board of Directors
March 03, 2020 08:00 ET
|
Orchestra BioMed
Ms. Yanchik Connealy will serve as the Audit Committee Chair, strengthening Orchestra BioMed’s financial reporting capabilities NEW HOPE, Pa., March 03, 2020 (GLOBE NEWSWIRE) -- Orchestra BioMed,...
Orchestra BioMed™ Secures $20 Million Financing Facility from Silicon Valley Bank
December 10, 2019 08:00 ET
|
Orchestra BioMed
NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs in...
Orchestra BioMed™ to Present at the Innovation in Cardiovascular Interventions Meeting and the CSI Focus D-HF Congress
December 05, 2019 08:00 ET
|
Orchestra BioMed
NEW HOPE, Pa., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs...
Orchestra BioMed™ to Present at the Canaccord Genuity MedTech and Diagnostics Forum and the 31st Annual Piper Jaffray Healthcare Conference
November 19, 2019 07:30 ET
|
Orchestra BioMed
NEW HOPE, Pa., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs...
Orchestra BioMed™ Strengthens Management Team with Appointments of Expert Product Development Leaders Juan A. Lorenzo and Paul V. Goode, Ph.D.
October 16, 2019 07:30 ET
|
Orchestra BioMed
NEW HOPE, Pa., Oct. 16, 2019 (GLOBE NEWSWIRE) -- Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs...
Orchestra BioMed Announces Late-Breaking Clinical Results Showing BackBeat Cardiac Neuromodulation Therapy™ Drives Significant Reduction in Systolic Blood Pressure
September 28, 2019 15:45 ET
|
Orchestra BioMed
Double-blind, randomized trial data demonstrates clinically meaningful and statistically significant difference of 8.1 mmHg in reduction of 24-hour ambulatory systolic blood pressure at 6 months vs....
Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease
September 17, 2019 07:30 ET
|
Orchestra BioMed
First and only non-coated sirolimus-eluting angioplasty balloon system to receive Breakthrough Device designation for below-the-knee disease Follows Breakthrough Device designation for Virtue...
Orchestra BioMed Receives CE Mark for BackBeat Cardiac Neuromodulation Therapy™ (CNT) for Hypertension
September 04, 2019 07:30 ET
|
Orchestra BioMed
NEW HOPE, Pa., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Orchestra BioMed™, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet...
Orchestra BioMed™ Appoints Dennis Donohoe, M.D., Leading Clinical Development Expert, as Chief Medical Officer
August 27, 2019 07:30 ET
|
Orchestra BioMed
NEW HOPE, Pa., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs...
Orchestra BioMed™ Completes $34 Million Financing to Accelerate Product Pipeline Development and Advance Partnerships
July 10, 2019 07:30 ET
|
Orchestra BioMed
Series B-1 Round Led by Perceptive, RTW and Soleus Capital with Strategic Participation from Terumo Corporation Secures $64 Million in 2019 Capital Inflows, Including $30 Million Upfront Payment from...